NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
47 hedge funds and large institutions have $9.3M invested in NeuBase Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 15 reducing their positions, and 6 closing their positions.
3% less capital invested
Capital invested by funds: $9.56M → $9.3M (-$263K)
8% less funds holding
Funds holding: 51 → 47 (-4)
60% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 15
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
75% less call options, than puts
Call options by funds: $236K | Put options by funds: $931K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$77.7K |
| 2 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$32.4K |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$15.1K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$14K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
-$155K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$144K |
| 3 |
Bank of New York Mellon
New York
|
-$64.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$52.9K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$48.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Nomura Holdings
Tokyo,
Japan
| – | -$37K | -33 | Closed |
|
|
LTFS
52
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$1K | -1 | Closed |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| – | -$1K | -1 | Closed |
|
NBSE Hedge Fund Activity: Q3 2016 in Review
47 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2016, worth a combined $9.3M — down 2.7% from $9.56M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NBSE and 2 opened new positions — a net loss of 4 holders — while 15 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $77.7K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $155K sold.
- 47 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2016, down from 51 in Q2 2016.
- Funds reported $9.3M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2016, down 2.7% quarter-over-quarter.
- 2 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2016 and 6 closed out, a net change of -4 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2016 was Renaissance Technologies, an estimated $77.7K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2016 was A.R.T. Advisors, an estimated $155K sold.
Based on aggregated 13F filings for Q3 2016.